EDG-15400

Phase 2Small molecule

EDG-15400 is one of 3 small molecule programs targeting Heart Failure With Preserved Ejection Fraction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart Failure With Preserved Ejection FractionRecruiting

Heart Failure With Preserved Ejection FractionPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Heart Failure With Preserved Ejection Fraction

#DrugCompanyPhaseTrials

Monoferric

PPharmacosmos A/S

Approved

2 2

Inpefa

LLexicon Pharmaceuticals

Approved

1 3

EDG-15400

EEdgewise Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Heart Failure With Preserved Ejection Fraction

NCT07795814

Clinical

Trials by Indication[1]

Heart Failure With Preserved Ejection Fraction1 trial

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

Recruiting·EEdgewise Therapeutics, Inc.·Phase 2·NCT07795814·90 enrolled

Unspecified1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Healthy Adults

Completed·EEdgewise Therapeutics, Inc.·Phase 1·NCT07177066·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EDG-15400. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EDG-15400 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EDG-15400. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Edgewise Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEdgewise Therapeutics, Inc.

EDG-15400

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Heart Failure With Preserved Ejection Fraction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News